Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
- 1 July 2013
- journal article
- Published by Elsevier BV in Cancer Cell
- Vol. 24 (1), 120-129
- https://doi.org/10.1016/j.ccr.2013.06.002
Abstract
No abstract availableThis publication has 39 references indexed in Scilit:
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer CellsCancer Cell, 2012
- Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomesNature Medicine, 2011
- Deciphering the rules of programmed cell death to improve therapy of cancer and other diseasesThe EMBO Journal, 2011
- A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER‐positive breast cancerThe Journal of Pathology, 2011
- Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737Proceedings of the National Academy of Sciences of the United States of America, 2011
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 2011
- BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy receivedBritish Journal of Cancer, 2010
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006